Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world’s greatest health challenges. Their medical device technology offers unparalleled transdermal activation of the homeostatic nuclei of the brainstem and hypothalamus, allowing for alterations in autonomic function, circadian regulation and neuro-metabolic influence.
Neurovalens’ core values hinge on the generation of robust clinical data that provide meaningful outcomes throughout the lives of our patients. The technology aims to provide drug-free solutions to the world’s greatest health epidemics.
IQ Capital invested in Neurovalens at Seed stage in 2019 and followed through to Series A in July 2020.
“The benefit of having IQ Capital as part of the team extends well beyond providing funding. I am extremely grateful for the sense of ambition and passion that IQ Capital see in the future of Neurovalens. If you have an exciting idea and are ready to move fast, then I would highly recommend reaching out the IQ team and finding out more about how they can help your company succeed.”